BioReperia

With our unique ZTX® platform (zebrafish tumor xenograft), it's possible to accelerate drug discovery and determine the best drug available for each patient within a few days. BioReperia is a Swedish contract research organization (CRO) developing new products to accelerate drug discovery, improve the diagnosis of cancer patients, and increase the success rate in clinical trials using zebrafish models. Our proprietary platform reduces the prediction time for the right anti-cancer treatment in individual cancer patients from 6 months to 5 days. It also allows metastasis invasion within 3 days, providing in vivo data on tumor regression and metastasis inhibition of compounds in less than a week. As an agile and highly customizable toolbox for drug discovery, our product can be applied to all cancer indications, using cell lines and patient-derived xenografts, as well as primary tumors from patients. This platform can accommodate all types of compounds, from small molecules to large peptides, antibodies, and ADCs. Additionally, it has been developed to include the evaluation of immuno-therapies. Why not save time and financial resources by having an in vivo model that accurately identifies drug candidates in less than a week? Learn more about our lead products for precision medicine (ZTX®Predict) and drug discovery (ZTX®Oncoleads). We are happy to discuss how we can collaborate. Please contact us at info@bioreperia.com.